Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Want to see ARCT full AI Analyst Report?
ARCT Stock Chart & Stats
$8.85
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.85
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.85 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$217.44M
Enterprise Value$33.42M
Total Cash (Recent Filing)$211.38M
Total Debt (Recent Filing)$19.68M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Aug 10, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding28,423,069
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit0.81
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$18.00Price Target Upside103.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.02
Revenue Forecast (FY)$17.05M
Bulls Say, Bears Say
Bulls Say
Platform & Delivery AdvantageArcturus' proprietary LUNAR delivery and mRNA purification enabled tolerable repeat inhaled dosing beyond one month. This technical differentiation supports a durable competitive edge in respiratory mRNA therapeutics, enabling at‑home dosing, improved adherence and a meaningful platform moat for CF and other inhaled indications.
Cash Runway & Balance-sheetA cash balance of $213.4M and a stated runway beyond Q2 2028 gives the company multi‑quarter visibility to advance pivotal clinical and regulatory milestones without immediate financing. Coupled with low leverage (debt-to-equity ~0.10), this materially reduces near-term solvency risk while supporting program execution.
Strategic PartnershipsEstablished manufacturing and commercialization partnerships (Meiji manufacturing KOSTAIVE; collaborations with BARDA and CSL Seqirus) de‑risk scale up and market access. These partner relationships provide manufacturing capacity, regulatory/commercial support and potential milestone/royalty revenue streams over time.
Bears Say
Revenue ContractionMaterial revenue decline (TTM down ~36.9% and a $27.3M quarterly drop) signals a structural pullback from prior pandemic-era vaccine income. Persistently lower top-line hurts operating leverage and makes it harder to absorb development costs, increasing reliance on milestones or new commercialized products to sustain operations.
Weak Cash GenerationSustained negative operating and free cash flow, with FCF worsening ~21% year over year, indicates ongoing cash burn from development activities. Even with current runway, persistent negative cash generation elevates medium‑term financing risk and could force dilutive raises or strategic trade-offs if revenue recovery stalls.
Clinical & Modality RiskThe small, open‑label design (up to ~20 subjects, no placebo) makes efficacy interpretation harder and increases regulatory uncertainty for a novel inhaled mRNA modality. A competitor's discontinuation of an inhaled CFTR mRNA trial highlights safety/modality risks and could raise scrutiny or require larger, costlier trials to convince regulators and payers.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.85 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $217.44M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 67 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $0.06.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 3.596%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (103.39% Upside)
$18.00 (103.39% Upside)
Hedge Fund Trend
Increased
By 91.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-36.55%
Trailing 12-Months
Asset Growth
-26.03%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
ARCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful clinical and regulatory progress — notably initiation of a 12‑week ARCT‑032 Phase II with tolerable repeat inhaled dosing and FDA clarity on ARCT‑810 pediatric path — supported by a strengthened leadership team and a cash runway through mid‑2028. Offsetting these positives were a material year‑over‑year revenue decline ($27.3M), a quarter‑over‑quarter cash decrease (~$19.4M, 8.3%), program‑specific manufacturing cost increases, and uncertainties tied to a small open‑label CF study and broader modality risk. On balance, the advancement of key programs and regulatory alignment outweigh the financial and operational headwinds in the near term.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$18.00
▲(103.39% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.04% Insiders
24.37% Mutual Funds
31.73% Other Institutional Investors
15.20% Public Companies and
Individual Investors